# Yext, Inc.: financial statements, quarterly

YEXT · NYSE · CIK 1614178 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/yext.md) · [Financials](/companies/yext/financials.md) · [Filings](/companies/yext/filings.md) · [Insiders](/companies/yext/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/yext/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [101](/filings/0001614178-24-000140.md) | [101 d](/filings/0001628280-26-016402.md) | [96.0](/filings/0001614178-25-000077.md) | [97.9](/filings/0001614178-25-000119.md) | [114](/filings/0001628280-25-055819.md) | [113 d](/filings/0001628280-26-016402.md) | [109](/filings/0001628280-26-039788.md) | [113](/filings/0001628280-26-059784.md) | [112](/filings/0001628280-25-055819.md) | [112 d](/filings/0001628280-26-016402.md) | [108](/filings/0001628280-26-039788.md) | [111](/filings/0001628280-26-059784.md) |
| Cost of revenue | $m | [22.1](/filings/0001614178-24-000140.md) | [21.7 d](/filings/0001628280-26-016402.md) | [21.5](/filings/0001614178-25-000077.md) | [22.3](/filings/0001614178-25-000119.md) | [26.2](/filings/0001628280-25-055819.md) | [26.3 d](/filings/0001628280-26-016402.md) | [27.1](/filings/0001628280-26-039788.md) | [28.1](/filings/0001628280-26-059784.md) | [29.2](/filings/0001628280-25-055819.md) | [29.7 d](/filings/0001628280-26-016402.md) | [29.2](/filings/0001628280-26-039788.md) | [27.3](/filings/0001628280-26-059784.md) |
| Gross profit | $m | [79.1](/filings/0001614178-24-000140.md) | [79.4 d](/filings/0001628280-26-016402.md) | [74.4](/filings/0001614178-25-000077.md) | [75.6](/filings/0001614178-25-000119.md) | [87.7](/filings/0001628280-25-055819.md) | [86.8 d](/filings/0001628280-26-016402.md) | [82.4](/filings/0001628280-26-039788.md) | [85.0](/filings/0001628280-26-059784.md) | [82.8](/filings/0001628280-25-055819.md) | [82.3 d](/filings/0001628280-26-016402.md) | [78.7](/filings/0001628280-26-039788.md) | [83.8](/filings/0001628280-26-059784.md) |
| Research and development | $m | [18.3](/filings/0001614178-24-000140.md) | [18.1 d](/filings/0001628280-26-016402.md) | [17.1](/filings/0001614178-25-000077.md) | [18.6](/filings/0001614178-25-000119.md) | [21.1](/filings/0001628280-25-055819.md) | [20.5 d](/filings/0001628280-26-016402.md) | [21.9](/filings/0001628280-26-039788.md) | [23.4](/filings/0001628280-26-059784.md) | [22.6](/filings/0001628280-25-055819.md) | [22.0 d](/filings/0001628280-26-016402.md) | [21.5](/filings/0001628280-26-039788.md) | [19.4](/filings/0001628280-26-059784.md) |
| Operating income | $m | [(1.8)](/filings/0001614178-24-000140.md) | [1.0 d](/filings/0001628280-26-016402.md) | [(5.4)](/filings/0001614178-25-000077.md) | [(7.6)](/filings/0001614178-25-000119.md) | [(10.4)](/filings/0001628280-25-055819.md) | [(9.1) d](/filings/0001628280-26-016402.md) | [1.1](/filings/0001628280-26-039788.md) | [29.7](/filings/0001628280-26-059784.md) | [7.8](/filings/0001628280-25-055819.md) | [6.0 d](/filings/0001628280-26-016402.md) | [5.6](/filings/0001628280-26-039788.md) | [17.6](/filings/0001628280-26-059784.md) |
| Interest expense | $m | [0.2](/filings/0001614178-24-000140.md) | [0.1 d](/filings/0001628280-26-016402.md) | [0.4](/filings/0001614178-25-000077.md) | [0.1](/filings/0001614178-25-000119.md) | [0.2](/filings/0001628280-25-055819.md) | [0.2 d](/filings/0001628280-26-016402.md) | [0.6](/filings/0001628280-26-039788.md) | [2.3](/filings/0001628280-26-059784.md) | [2.4](/filings/0001628280-25-055819.md) | [2.3 d](/filings/0001628280-26-016402.md) | [3.1](/filings/0001628280-26-039788.md) | [3.6](/filings/0001628280-26-059784.md) |
| Income tax | $m | [0.4](/filings/0001614178-24-000140.md) | [0.9 d](/filings/0001628280-26-016402.md) | [0.2](/filings/0001614178-25-000077.md) | [(1.4)](/filings/0001614178-25-000119.md) | [3.0](/filings/0001628280-25-055819.md) | [(1.9) d](/filings/0001628280-26-016402.md) | [(0.0)](/filings/0001628280-26-039788.md) | [1.8](/filings/0001628280-26-059784.md) | [0.5](/filings/0001628280-25-055819.md) | [(0.0) d](/filings/0001628280-26-016402.md) | [0.4](/filings/0001628280-26-039788.md) | [1.1](/filings/0001628280-26-059784.md) |
| Net income | $m | [(0.5)](/filings/0001614178-24-000140.md) | [1.7 d](/filings/0001628280-26-016402.md) | [(3.8)](/filings/0001614178-25-000077.md) | [(4.1)](/filings/0001614178-25-000119.md) | [(12.8)](/filings/0001628280-25-055819.md) | [(7.3) d](/filings/0001628280-26-016402.md) | [0.8](/filings/0001628280-26-039788.md) | [26.8](/filings/0001628280-26-059784.md) | [6.1](/filings/0001628280-25-055819.md) | [4.2 d](/filings/0001628280-26-016402.md) | [2.6](/filings/0001628280-26-039788.md) | [13.1](/filings/0001628280-26-059784.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001614178-24-000140.md) | not reported | [(0.03)](/filings/0001614178-25-000077.md) | [(0.03)](/filings/0001614178-25-000119.md) | [(0.10)](/filings/0001628280-25-055819.md) | not reported | [0.01](/filings/0001628280-26-039788.md) | [0.03](/filings/0001628280-26-059784.md) | [0.01](/filings/0001628280-25-055819.md) | not reported | [0.02](/filings/0001628280-26-039788.md) | [0.13](/filings/0001628280-26-059784.md) |
| Basic EPS | $ per share | [0.00](/filings/0001614178-24-000140.md) | not reported | [(0.03)](/filings/0001614178-25-000077.md) | [(0.03)](/filings/0001614178-25-000119.md) | [(0.10)](/filings/0001628280-25-055819.md) | not reported | [0.01](/filings/0001628280-26-039788.md) | [0.22](/filings/0001628280-26-059784.md) | [0.05](/filings/0001628280-25-055819.md) | not reported | [0.02](/filings/0001628280-26-039788.md) | [0.13](/filings/0001628280-26-059784.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [182](/filings/0001614178-24-000140.md) | [210](/filings/0001628280-26-016402.md) | [246](/filings/0001614178-25-000077.md) | [235](/filings/0001614178-25-000119.md) | [100](/filings/0001628280-25-055819.md) | [123](/filings/0001628280-26-016402.md) | [115](/filings/0001628280-26-039788.md) | [179](/filings/0001628280-26-059784.md) | [140](/filings/0001628280-25-055819.md) | [154](/filings/0001628280-26-059784.md) | [91.9](/filings/0001628280-26-039788.md) | [86.8](/filings/0001628280-26-059784.md) |
| Current assets | $m | [279](/filings/0001614178-23-000101.md) | [360](/filings/0001614178-25-000030.md) | [340](/filings/0001614178-24-000056.md) | [322](/filings/0001614178-24-000104.md) | [209](/filings/0001614178-24-000140.md) | [286](/filings/0001628280-26-016402.md) | [247](/filings/0001614178-25-000077.md) | [300](/filings/0001614178-25-000119.md) | [243](/filings/0001628280-25-055819.md) | [318](/filings/0001628280-26-059784.md) | [208](/filings/0001628280-26-039788.md) | [199](/filings/0001628280-26-059784.md) |
| Total assets | $m | [432](/filings/0001614178-23-000101.md) | [509](/filings/0001614178-25-000030.md) | [482](/filings/0001614178-24-000056.md) | [458](/filings/0001614178-24-000104.md) | [540](/filings/0001614178-24-000140.md) | [610](/filings/0001628280-26-016402.md) | [572](/filings/0001614178-25-000077.md) | [626](/filings/0001614178-25-000119.md) | [556](/filings/0001628280-25-055819.md) | [622](/filings/0001628280-26-059784.md) | [499](/filings/0001628280-26-039788.md) | [484](/filings/0001628280-26-059784.md) |
| Current liabilities | $m | [199](/filings/0001614178-23-000101.md) | [268](/filings/0001614178-25-000030.md) | [236](/filings/0001614178-24-000056.md) | [208](/filings/0001614178-24-000104.md) | [241](/filings/0001614178-24-000140.md) | [345](/filings/0001628280-26-016402.md) | [327](/filings/0001614178-25-000077.md) | [286](/filings/0001614178-25-000119.md) | [222](/filings/0001628280-25-055819.md) | [297](/filings/0001628280-26-059784.md) | [264](/filings/0001628280-26-039788.md) | [240](/filings/0001628280-26-059784.md) |
| Total liabilities | $m | [295](/filings/0001614178-23-000101.md) | [362](/filings/0001614178-25-000030.md) | [326](/filings/0001614178-24-000056.md) | [295](/filings/0001614178-24-000104.md) | [380](/filings/0001614178-24-000140.md) | [457](/filings/0001628280-26-016402.md) | [430](/filings/0001614178-25-000077.md) | [474](/filings/0001614178-25-000119.md) | [401](/filings/0001628280-25-055819.md) | [462](/filings/0001628280-26-059784.md) | [475](/filings/0001628280-26-039788.md) | [448](/filings/0001628280-26-059784.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-25-055819.md) | not reported | [98.3](/filings/0001614178-25-000119.md) | [98.2](/filings/0001628280-25-055819.md) | [98.0](/filings/0001628280-26-059784.md) | [148](/filings/0001628280-26-039788.md) | [148](/filings/0001628280-26-059784.md) |
| Shareholders' equity | $m | [136](/filings/0001614178-24-000140.md) | [147](/filings/0001628280-26-016402.md) | [156](/filings/0001614178-25-000119.md) | [163](/filings/0001628280-25-055819.md) | [160](/filings/0001628280-25-055819.md) | [153](/filings/0001628280-26-059784.md) | [142](/filings/0001628280-26-059784.md) | [153](/filings/0001628280-26-059784.md) | [155](/filings/0001628280-25-055819.md) | [159](/filings/0001628280-26-059784.md) | [24.5](/filings/0001628280-26-059784.md) | [35.7](/filings/0001628280-26-059784.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.6) d](/filings/0001614178-24-000140.md) | [28.0 d](/filings/0001628280-26-016402.md) | [38.3](/filings/0001614178-25-000077.md) | [(10.6) d](/filings/0001614178-25-000119.md) | [(15.8) d](/filings/0001628280-25-055819.md) | [38.3 d](/filings/0001628280-26-016402.md) | [37.7](/filings/0001628280-26-039788.md) | [8.4 d](/filings/0001628280-26-059784.md) | [(19.8) d](/filings/0001628280-25-055819.md) | [29.5 d](/filings/0001628280-26-016402.md) | [37.4](/filings/0001628280-26-039788.md) | [7.9 d](/filings/0001628280-26-059784.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001614178-24-000140.md) | [0.4 d](/filings/0001628280-26-016402.md) | [0.6](/filings/0001614178-25-000077.md) | [0.5 d](/filings/0001614178-25-000119.md) | [0.6 d](/filings/0001628280-25-055819.md) | [0.3 d](/filings/0001628280-26-016402.md) | [0.6](/filings/0001628280-26-039788.md) | [0.6 d](/filings/0001628280-26-059784.md) | [0.5 d](/filings/0001628280-25-055819.md) | [0.9 d](/filings/0001628280-26-016402.md) | [0.4](/filings/0001628280-26-039788.md) | [0.3 d](/filings/0001628280-26-059784.md) |
| Share repurchases | $m | [12.1 d](/filings/0001614178-24-000140.md) | [0.0 d](/filings/0001628280-26-016402.md) | [0.0](/filings/0001614178-25-000077.md) | [0.2 d](/filings/0001614178-25-000119.md) | [6.6 d](/filings/0001628280-25-055819.md) | [11.1 d](/filings/0001628280-26-016402.md) | [27.6](/filings/0001628280-26-039788.md) | [17.7 d](/filings/0001628280-26-059784.md) | [14.4 d](/filings/0001628280-25-055819.md) | [7.7 d](/filings/0001628280-26-016402.md) | [142](/filings/0001628280-26-039788.md) | [8.9 d](/filings/0001628280-26-059784.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [124](/filings/0001614178-23-000101.md) | [123](/filings/0001614178-24-000056.md) | [124](/filings/0001614178-24-000104.md) | [124](/filings/0001614178-24-000140.md) | [125](/filings/0001614178-25-000077.md) | [127](/filings/0001614178-25-000119.md) | [128](/filings/0001628280-25-055819.md) | [131](/filings/0001628280-26-039788.md) | [131](/filings/0001628280-26-059784.md) | [129](/filings/0001628280-25-055819.md) | [113](/filings/0001628280-26-039788.md) | [103](/filings/0001628280-26-059784.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 98,978,704 at 2026-08-18, from the cover of the [10-Q filed 2026-09-01](/filings/0001628280-26-059784.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.